We are monitoring the impact of COVID-19 on Antivenom Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1501
Share on
Share on

Global Antivenom Market Size, Share, Trends & Growth Analysis Report – Segmented By Type, Animal & Region – Industry Forecast (2020 to 2025)

Pulished: February, 2020
ID: 1501
Pages: 175

Global Antivenom Market Size (2020 to 2025)

As per our report, the Antivenom Market size at a global level is expected to reach USD 1.9 billion by 2025 from USD 2.6 billion in 2020, growing at a CAGR of 6.18% between 2020 to 2025.

Antivenom is a biological product used to treat poisonous bites or stings of spiders, snakes, scorpions, and others. Snake bites are one of the major threats which can be fatal, and every year so many people are dying around the world due to lack of treatment on time. Antivenoms should be used with proper knowledge while treating the snake bites. It may not be active or may lead to other side effects. There are two types of antivenom, which are known as monovalent and polyvalent.

MARKET DRIVERS:

The rise in the incidence of snake bites and people getting aware of treatments due to modernization and globalization leads to constant growth in demand of the antivenom market across the world. According to the World Health Organization (WHO), around 5.5 million snake bites occur each year, resulting in up to 2.8 million poisonings (snakebite poisoning), and at least 85,000 to 143,000 people die from snakebites. Besides, about three times more amputations and other permanent disabilities. Due to international health organizations' involvement in the production of safe and effective antidotes, people are familiar with antivenom drugs. The production of antivenom is difficult and expensive.

Government authorities in developing countries are taking measures to prevent loss of life due to snake bites and other venomous bites to enhance healthcare services, fuelling the growth of the antivenom market. Medical research organizations are also continually developing effective treatment methods and antivenom to tackle the seriousness of venomous bites, catalyzing the business.

Rising awareness among people and recognizing the snakebite as a medical emergency in rural areas is expected to boost the demand for snakebites' treatments, which will offer growth opportunities for the antivenom market during the forecast period. Rising focus on research and development activities from the private and public organizations for developing high-quality antivenoms owing to immense advancements in medical science and technology to meet the continuously rising demand for the antivenoms due to the rise in mortality rate is expected to create more growth opportunities for the market over the forecast period. The market is supposed to offer several options for the key players owing to the unmet demand for antivenoms in countries like Africa, Asia, and Latin America. An increasing number of novel product developments and launches and a more natural approval process are also foreseen to create lucrative growth opportunities for the global antivenom market during the forecast period.

MARKET RESTRAINTS:

Uncertainties in standards of quality and improper application of antivenom limit the growth rate of the global antivenom market. High costs associated with manufacturing and lack of proper investments by public and private organizations, and inefficient manufacturing procedures are restraining the growth of the global antivenom market. Other factors that are challenging the development of the market are inappropriate regulations, shortage of skilled professionals in drug control laboratories, lack of specifications and proper knowledge regarding the types of toxic and lethal venom types which would affect the treatment procedure, belief systems in some countries like India and particularly in rural areas where the incidence of snake bites are more frequent, and lack of proper distribution networks of venom due to the inadequate infrastructure of healthcare in developing countries.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2019 to 2025

Base Year

2019

Forecast Period

2020 to 2025

Segments Covered

By Type, Animal and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

This research report on the global antivenom market has been segmented and sub-segmented based on type, animal, and region.

Antivenom Market - By Type:

  • Vaccines
  • Hyperimmune Sera
    • Homologous
    • Heterologous

Antivenom Market - By Animal:

  • Snakes
  • Scorpions
  • Spiders
  • Others

Based on animals, the Snakes segment dominates the market and is likely to continue the trend during the forecast period. Factors such as the occurrence rate of snake bites in countries like India, Pakistan, Bangladesh, and other Asian and African countries lead to a constant rise in demand for antivenom in these countries. Increasing awareness among people in rural areas about the seriousness of snakebites, unmet demand conditions of the antivenoms, improvisation of regulatory frameworks and approval procedures, and increased government investments for developing high-quality antivenoms contributes to the growth of the snake segment in this market.

Antivenom Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Geographically, North America is the dominating global antivenom market accounting for approximately 39.0%, followed by Europe in 2019. Asia-Pacific is estimated to be the fastest-growing region with a CAGR of 8.59% during the forecast period of 2020 to 2025.

NOTEWORTHY COMPANIES IN THE MARKET

Companies leading the Global Antivenom Market profiled in the report are Instituto Bioclon, S.A. de C.V. (Mexico), Pfizer AG (Switzerland), CSL Limited (Australia), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co., Inc. (U.S.), Rare Disease Therapeutics, Inc. (U.S.), Vins Bioproducts Limited (India), BTG Plc (U.K.), Incepta Vaccine Ltd. (Bangladesh) and Bharat Serum.

RECENT MARKET DEVELOPMENTS

  • In May 2019: snakebite crisis organization raised funds for developing high-quality and treatment enhancing antivenoms to meet the continually rising need for antivenoms.
  • In 2018: Pzifer Company extended the expiration date up to 12 months for its product called antivenin with food and drug administration.
  • In 2018: the University of Arizona had developed an antivenom called polyvalent F(ab)2 Equine, which can be used for treating bite caused by a snake in North America called Micrurus.
  • May 2017: Snakebite911, an app that contains educational information on snakes and snakes bite first-aid support, developed by BTG PLC.

1. Introduction                        

            1.1 Market Definition            

            1.2 Study Deliverables                       

            1.3 Base Currency, Base Year and Forecast Periods              

            1.4 General Study Assumptions                     

2. Research Methodology

            2.1 Introduction                     

            2.2 Research Phases              

                        2.2.1 Secondary Research     

                        2.2.2 Primary Research         

                        2.2.3 Econometric Modelling

                        2.2.4 Expert Validation          

            2.3 Analysis Design                

            2.4 Study Timeline                

3. Overview

            3.1 Executive Summary                     

            3.2 Key Inferences                 

            3.3 Epidemology                    

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

            4.1 Market Drivers                 

            4.2 Market Restraints            

            4.3 Key Challenges                 

            4.4 Current Opportunities in the Market                  

5. Market Segmentation

            5.1 Type                     

                        5.1.1 Introduction      

                        5.1.2 Vaccines

                        5.1.3 Hyperimmune Sera       

                                    5.1.3.1 Homologous

                                    5.1.3.2 Heterologous

                        5.1.4  Y-o-Y Growth Analysis, By type            

                        5.1.5  Market Attractiveness Analysis, By Type         

                        5.1.6  Market Share Analysis, By Type           

            5.2 Animal                  

                        5.2.1 Introduction      

                        5.2.2 Snakes   

                        5.2.3 Scorpions           

                        5.2.4 Spiders  

                        5.2.5 Others   

                        5.2.6  Y-o-Y Growth Analysis, By Animal       

                        5.2.7  Market Attractiveness Analysis, By Animal     

                        5.2.8  Market Share Analysis, By Animal       

6. Geographical Analysis

            6.1 Introduction                     

                        6.1.1 Regional Trends

                        6.1.2 Impact Analysis 

                        6.1.3 Y-o-Y Growth Analysis  

                                    6.1.3.1 By Geographical Area

                                    6.1.3.2 By Type

                                    6.1.3.2 By Animal

                        6.1.4  Market Attractiveness Analysis

                                    6.1.4.1 By Geographical Area

                                    6.1.4.2 By Type

                                    6.1.4.2 By Animal

                        6.1.5  Market Share Analysis 

                                    6.1.5.1 By Geographical Area

                                    6.1.5.2 By Type

                                    6.1.5.2 By Animal

            6.2 North America                 

                        6.1.1 Introduction      

                        6.1.2 United States    

                        6.1.3 Canada  

            6.3 Europe                  

                        6.2.1 Introduction      

                        6.2.2 U.K         

                        6.2.3 Spain     

                        6.2.4 Germany

                        6.2.5 Italy       

                        6.2.6 France   

            6.4 Asia-Pacific                       

                        6.3.1 Introduction      

                        6.3.2 China     

                        6.3.3 India      

                        6.3.4 Japan     

                        6.3.5 Australia

                        6.3.6 South Korea      

            6.5 Latin America                   

                        6.4.1 Introduction      

                        6.4.2 Brazil     

                        6.4.3 Argentina          

                        6.4.4 Mexico  

                        6.4.5 Rest of Latin America   

            6.6 Middle East & Africa                    

                        6.5.1 Introduction      

                        6.5.2 Middle-East       

                        6.5.3 Africa    

7.Strategic Analysis                            

            7.1 PESTLE analysis                

                        7.1.1 Political 

                        7.1.2 Economic          

                        7.1.3 Social     

                        7.1.4 Technological    

                        7.1.5 Legal     

                        7.1.6 Environmental  

            7.2 Porter’s Five analysis                   

                        7.2.1 Bargaining Power of Suppliers  

                        7.2.2 Bargaining Power of Consumers          

                        7.2.3 Threat of New Entrants

                        7.2.4 Threat of Substitute Products and Services     

                        7.2.5 Competitive Rivalry within the Industry           

8.Market Leaders' Analysis                            

            8.1 Instituto Bioclon, S.A. de C.V.                  

                        8.1.1 Overview           

                        8.1.2 Product Analysis

                        8.1.3 Financial analysis          

                        8.1.4 Recent Developments   

                        8.1.5 SWOT analysis  

                        8.1.6 Analyst View     

            8.2 Pfizer AG              

            8.3 CSL Limited                      

            8.4 Roche                   

            8.5 Merck & Co                      

            8.6 Rare Disease Therapeutics, Inc.               

            8.7 Vins Bioproducts Limited             

            8.8 BTG Plc                 

            8.9 Incepta Vaccine Ltd                      

            8.10 Bharat Serim and Vaccines Limited (BSV)                     

9. Competitive Landscape                              

            9.1 Market share analysis                  

            9.2 Merger and Acquisition Analysis             

            9.3 Agreements, collaborations and Joint Ventures             

            9.4 New Product Launches                

10. Market Outlook and Investment Opportunities                           

Appendix                                

            a) List of Tables

            b) List of Figures

  • Global, Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Antivenom Market, By Region, From 2020 to 2025 (USD Million)
  2. Global Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  3. Global Vaccines Market, By Region, From 2020 to 2025 (USD Million)
  4. Global Hyperimmune Sera Market, By Region, From 2020 to 2025 (USD Million)
  5. Global Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  6. Global Snakes Market, By Region, From 2020 to 2025 (USD Million)
  7. Global Scorpions Market, By Region, From 2020 to 2025 (USD Million)
  8. Global Spiders Market, By Region, From 2020 to 2025 (USD Million)
  9. Global Others Market, By Region, From 2020 to 2025 (USD Million)
  10. Global Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  11. Global Homologous Market, By Region, From 2020 to 2025 (USD Million)
  12. Global Heterologous Market, By Region, From 2020 to 2025 (USD Million)
  13. North America Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  14. North America Vaccines Market, By Region, From 2020 to 2025 (USD Million)
  15. North America Hyperimmune Sera Market, By Region, From 2020 to 2025 (USD Million)
  16. North America Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  17. North America Snakes Market, By Region, From 2020 to 2025 (USD Million)
  18. North America Scorpions Market, By Region, From 2020 to 2025 (USD Million)
  19. North America Spiders Market, By Region, From 2020 to 2025 (USD Million)
  20. North America Others Market, By Region, From 2020 to 2025 (USD Million)
  21. United States Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  22. United States Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  23. Canada Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  24. Canada Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  25. North America Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  26. North America Homologous Market, By Region, From 2020 to 2025 (USD Million)
  27. North America Heterologous Market, By Region, From 2020 to 2025 (USD Million)
  28. United States Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  29. Canada Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  30. Europe Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  31. Europe Vaccines Market, By Region, From 2020 to 2025 (USD Million)
  32. Europe Hyperimmune Sera Market, By Region, From 2020 to 2025 (USD Million)
  33. Europe Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  34. Europe Snakes Market, By Region, From 2020 to 2025 (USD Million)
  35. Europe Scorpions Market, By Region, From 2020 to 2025 (USD Million)
  36. Europe Spiders Market, By Region, From 2020 to 2025 (USD Million)
  37. Europe Others Market, By Region, From 2020 to 2025 (USD Million)
  38. U.K. Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  39. U.K. Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  40. Germany Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  41. Germany Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  42. France Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  43. France Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  44. Italy Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  45. Italy Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  46. Spain Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  47. Spain Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  48. Europe Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  49. Europe Homologous Market, By Region, From 2020 to 2025 (USD Million)
  50. Europe Heterologous Market, By Region, From 2020 to 2025 (USD Million)
  51. U.K. Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  52. Germany Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  53. France Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  54. Italy Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  55. Spain Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  56. Asia Pacific Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  57. Asia Pacific Vaccines Market, By Region, From 2020 to 2025 (USD Million)
  58. Asia Pacific Hyperimmune Sera Market, By Region, From 2020 to 2025 (USD Million)
  59. Asia Pacific Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  60. Asia Pacific Snakes Market, By Region, From 2020 to 2025 (USD Million)
  61. Asia Pacific Scorpions Market, By Region, From 2020 to 2025 (USD Million)
  62. Asia Pacific Spiders Market, By Region, From 2020 to 2025 (USD Million)
  63. Asia Pacific Others Market, By Region, From 2020 to 2025 (USD Million)
  64. Japan Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  65. Japan Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  66. China Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  67. China Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  68. India Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  69. India Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  70. Australia Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  71. Australia Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  72. South Korea Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  73. South Korea Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  74. Asia Pacific Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  75. Asia Pacific Homologous Market, By Region, From 2020 to 2025 (USD Million)
  76. Asia Pacific Heterologous Market, By Region, From 2020 to 2025 (USD Million)
  77. Japan Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  78. China Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  79. India Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  80. Australia Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  81. Latin America Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  82. Latin America Vaccines Market, By Region, From 2020 to 2025 (USD Million)
  83. Latin America Hyperimmune Sera Market, By Region, From 2020 to 2025 (USD Million)
  84. Latin America Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  85. Latin America Snakes Market, By Region, From 2020 to 2025 (USD Million)
  86. Latin America Scorpions Market, By Region, From 2020 to 2025 (USD Million)
  87. Latin America Spiders Market, By Region, From 2020 to 2025 (USD Million)
  88. Latin America Others Market, By Region, From 2020 to 2025 (USD Million)
  89. Brazil Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  90. Brazil Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  91. Argentina Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  92. Argentina Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  93. Mexico Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  94. Mexico Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  95. Rest of Latin America Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  96. Rest of Latin America Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  97. Latin America Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  98. Latin America Homologous Market, By Region, From 2020 to 2025 (USD Million)
  99. Latin America Heterologous Market, By Region, From 2020 to 2025 (USD Million)
  100. Brazil Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  101. Argentina Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  102. Mexico Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  103. Middle East and Africa Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  104. Middle East and Africa Vaccines Market, By Region, From 2020 to 2025 (USD Million)
  105. Middle East and Africa Hyperimmune Sera Market, By Region, From 2020 to 2025 (USD Million)
  106. Middle East and Africa Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  107. Middle East and Africa Snakes Market, By Region, From 2020 to 2025 (USD Million)
  108. Middle East and Africa Scorpions Market, By Region, From 2020 to 2025 (USD Million)
  109. Middle East and Africa Spiders Market, By Region, From 2020 to 2025 (USD Million)
  110. Middle East and Africa Others Market, By Region, From 2020 to 2025 (USD Million)
  111. Middle East Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  112. Middle East Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  113. Africa Antivenom Market, By Type, From 2020 to 2025 (USD Million)
  114. Africa Antivenom Market, By Animal, From 2020 to 2025 (USD Million)
  115. Middle East and Africa Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  116. Middle East and Africa Homologous Market, By Region, From 2020 to 2025 (USD Million)
  117. Middle East and Africa Heterologous Market, By Region, From 2020 to 2025 (USD Million)
  118. Middle East Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)
  119. Africa Antivenom Market, By Hyperimmune Sera, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample